Teva Pharmaceutical Industries Ltd., (TEVA) said it has launched the generic equivalent to Campral, or acamprosate calcium, delayed-release tablets, 333 mg, in the U.S.
Acamprosate calcium delayed-release tablets are used for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at the start of treatment.
Treatment with acamprosate calcium delayed-release tablets helps maintain abstinence from alcohol only when used as part of a treatment program that includes counseling and support.
Acamprosate calcium delayed-release tablets had annual sales of about $14 million in the U.S., according to IMS data as of December 2015. With over 375 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market.
by RTT Staff Writer